Pfizer Inc (PFE)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$22.71
Buy
$22.72
$0.58 (+2.63%)
Prices updated at 15 May 2025, 11:03 EDT
| Prices minimum 15 mins delay
Prices in USD
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 59,553m | 63,627m | |
| 34,599m | 45,776m | |
| 4,416m | 14,938m | |
| 7.42 | 23.48 | |
| 2,119m | 8,031m | |
| 9,557m | 18,127m | |
| Sales, General and administrative | 14,771m | 14,730m |
| Interest expenses | 2,209m | 3,091m |
| Provision for income taxes | -1,115m | -28m |
| Operating expenses | 30,183m | 30,838m |
| Income before taxes | 1,058m | 8,023m |
| Net income available to common shareholders | 2,119m | 8,031m |
| 0.38 | 1.42 | |
| Net interest income | -585m | -2,546m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.37 | 1.41 |
| Free cash flow per share | 1.4293 | 1.4539 |
| Book value/share | 17.1686 | 16.2848 |
| Debt equity ratio | 0.679657 | 0.642869 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 43,333m | 50,358m |
| Current liabilities | 47,794m | 42,995m |
| Total capital | 149,513m | 144,906m |
| Total debt | 70,845m | 63,649m |
| Total equity | 89,014m | 88,203m |
| Total non current liabilities | - | - |
| Loans | 60,499m | 56,703m |
| Total assets | 226,501m | 213,396m |
| Total liabilities | - | - |
| Cash and cash equivalents | 2,853m | 1,043m |
| Common stock | 5,646m | 5,667m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 468m | 2,917m |
| Cash dividends paid | -9,247m | -9,512m |
| 4,793m | 9,835m | |
| Investments (gains) losses | -32,278m | 2,652m |
| 2,917m | 1,107m | |
| Net income | - | - |
| 8,700m | 12,744m | |
| -3,907m | -2,909m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
